Last reviewed: April 21, 2026 Updated with Phase 3 TRIUMPH-4 data Primary sources: NEJM, Eli Lilly, ClinicalTrials.gov Retatrutide is a triple agonist (GLP-1 + GIP + glucagon) currently in Phase 3 trials, showing stronger early weight loss data
Egorova N, Dhollander T, Khlif MS et al (2020) Pervasive white matter fiber degeneration in ischemic stroke
[1] [25] The kidneys contribute to overall homeostasis in the body, including carnitine levels
Acquired deficiencies due to liver disease or vitamin K deficiency also impair clotting cascade proteins and increase bleeding tendency
Pterfi Z, Szilvsy-Szab A, Farkas E, et al
If done wrong, the drug might not work as well